BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
2024年3月6日 - 1:53PM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a
commercial-stage biopharmaceutical company focused on genetic
diseases and cancers, today announced the pricing on March 5, 2024
of an underwritten public offering of 8,620,690 shares of its
common stock at a public offering price of $29.00 per share, before
deducting underwriting discounts and commissions. In addition,
BridgeBio has granted the underwriters a 30-day option to purchase
up to an additional 1,293,103 shares of its common stock on the
same terms and conditions. The gross proceeds from the offering,
before deducting underwriting discounts and commissions and
offering expenses, are expected to be approximately $250.0 million,
excluding any exercise of the underwriters' option to purchase
additional shares. All of the shares in the offering to be sold by
BridgeBio.
J.P. Morgan, Cantor and Mizuho are acting as joint book-running
managers for the offering. Raymond James is acting as lead manager.
The offering is expected to close on or about March 8, 2024,
subject to the satisfaction of customary closing conditions.
The shares of common stock are being offered by BridgeBio
pursuant to an effective shelf registration statement on Form
S-3ASR (File No. 333-271650) that was previously filed with the
U.S. Securities and Exchange Commission (SEC) on May 4, 2023 and
automatically became effective upon filing. A preliminary
prospectus supplement and accompanying prospectus relating to and
describing the terms of the offering was filed with the SEC on
March 4, 2024. The final prospectus supplement and accompanying
prospectus relating to the offering will be filed with the SEC and
may be obtained, when available, from J.P. Morgan Securities LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717, by telephone at (866) 803-9204, or by
email at prospectus-eqfi@jpmorganchase.com; Cantor Fitzgerald &
Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor,
New York, NY 10022, or by email at prospectus@cantor.com; Mizuho
Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue
of the Americas, 3rd Floor, New York, New York 10020, by telephone
at 1-212-205-7602 or by email at US-ECM@mizuhogroup.com; or by
accessing the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About BridgeBio
BridgeBio is a commercial-stage biopharmaceutical company
founded to discover, create, test and deliver transformative
medicines to treat patients who suffer from genetic diseases and
cancers with clear genetic drivers. BridgeBio’s pipeline of
development programs ranges from early science to advanced clinical
trials. BridgeBio was founded in 2015 and its team of experienced
drug discoverers, developers and innovators are committed to
applying advances in genetic medicine to help patients as quickly
as possible.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding BridgeBio’s anticipated public offering. The words “may,”
“might,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,”
“predict,” “future,” “project,” “potential,” “continue,” “target”
and similar words or expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Any forward-looking statements in this press release, such as
the intended offering terms, are based on management’s current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, uncertainties related to market
conditions, statements about the expected gross proceeds from the
offering, and the completion of the offering on the anticipated
terms or at all. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in BridgeBio’s Annual Report on Form 10-K for the year ended
December 31, 2023, as well as discussions of potential risks,
uncertainties, and other important factors in BridgeBio’s other
filings with the SEC, including those contained or incorporated by
reference in the preliminary prospectus supplement and accompanying
prospectus related to the public offering filed with the SEC. In
addition, any forward-looking statements contained in this press
release represent the BridgeBio’s views only as of the date hereof
and should not be relied upon as representing its views as of any
subsequent date. BridgeBio explicitly disclaims any obligation to
update any forward-looking statements, except as required by law.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
BridgeBio Contact:Vikram
Balicontact@bridgebio.com(650) 789-8220
BridgeBio Pharma (NASDAQ:BBIO)
過去 株価チャート
から 4 2024 まで 5 2024
BridgeBio Pharma (NASDAQ:BBIO)
過去 株価チャート
から 5 2023 まで 5 2024